Drug profile · INN
pacritinib citrate
VONJO
pacritinib citrate (VONJO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — pacritinib citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
pacritinib citrate (VONJO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Activin receptor type-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pacritinib citrate?
pacritinib citrate (VONJO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pacritinib citrate?
VONJO is a marketed brand name for pacritinib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pacritinib citrate?
pacritinib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.